IgA Nephropathy (IgAN) Clinical Trial Insight, Pipeline Assessment, Emerging Drugs and Companies by DelveInsight

August 06 06:12 2020
“IgA Nephropathy (IgAN) Pipeline Insight, 2020”

 

(Albany, NY) DelveInsight has launched a new report on “IgA Nephropathy (IgAN) Pipeline Insight, 2020”.

 

IgA Nephropathy (IgAN) Pipeline Insight 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the IgA Nephropathy (IgAN) market. A detailed picture of the IgA Nephropathy (IgAN) pipeline landscape is provided, which includes the disease overview and IgA Nephropathy (IgAN) treatment guidelines.

The assessment part of the report embraces in-depth IgA Nephropathy (IgAN) commercial assessment and clinical assessment of the IgA Nephropathy (IgAN) pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, IgA Nephropathy (IgAN) collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

 

Key Companies Covered:

  • Novartis
  • Omeros Corporation
  • Calliditas Therapeutics
  • Apellis Pharmaceuticals
  • Aravive
  • Ionis
  • Aduro
  • And Many Others

 

Request for Free Sample Page: https://www.delveinsight.com/sample-request/iga-nephropathy-igan-pipeline-insight

 

Some of the Drugs Covered:

  • AVB-S6-500
  • BION-1301
  • IONIS-FB-LRx

And Many Others.

 

Scope of the Report:

  • The report covers the descriptive overview of IgA Nephropathy (IgAN) , explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the IgA Nephropathy (IgAN) epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for IgA Nephropathy (IgAN) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of IgA Nephropathy (IgAN) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global IgA Nephropathy (IgAN) market

 

Request for Free Sample Page: https://www.delveinsight.com/sample-request/iga-nephropathy-igan-pipeline-insight

 

IgA nephropathy also known as Berger’s disease, is a kidney disease that occurs when IgA deposits build up in the kidneys, causing inflammation that damages kidney tissues. IgA is an antibody—a protein made by the immune system to protect the body from foreign substances such as bacteria or viruses. Most people with IgA nephropathy receive care from a nephrologist, a doctor who specializes in treating people with kidney disease.

 

People who have this condition most often present with one or recurrent episodes of having blood in their urine (visible hematuria). These episodes usually occur during or right after an upper respiratory tract infection such as a cold, sore throat or a gastrointestinal infection.

IgA nephropathy usually doesn’t cause symptoms in the early stages, so the disease can go unnoticed for years or decades. It’s sometimes suspected when routine tests reveal protein and red blood cells in your urine that can’t be seen without a microscope (microscopic hematuria). In its early stages, IgA nephropathy may have no symptoms; it can be silent for years or even decades. Once symptoms appear, the most common one is hematuria, or blood in the urine. Hematuria can be a sign of damaged glomeruli. Blood in the urine may appear during or soon after a cold, sore throat, or other respiratory infection. The amount of blood may be: visible with the naked eye. The urine may turn pink or the color of tea or cola. Sometimes a person may have dark or bloody urine so small that it can only be detected using special medical tests.

Another symptom of IgA nephropathy is albuminuria—when a person’s urine contains an increased amount of albumin, a protein typically found in the blood, or large amounts of protein in the urine.

 

Request for Free Sample Page: https://www.delveinsight.com/sample-request/iga-nephropathy-igan-pipeline-insight

 

Table of Contents:

1. Report Introduction

2. IgA Nephropathy (IgAN) 

2.1. Overview

2.2. History 

2.3. IgA Nephropathy (IgAN) Symptoms

2.4. Causes

2.5.Pathophysiology

2.6. IgA Nephropathy (IgAN) Diagnosis 

2.6.1. Diagnostic Guidelines

3. IgA Nephropathy (IgAN) Current Treatment Patterns

3.1. IgA Nephropathy (IgAN) Treatment Guidelines

4. IgA Nephropathy (IgAN) – DelveInsight’s Analytical Perspective

4.1. In-depth Commercial Assessment

4.1.1. IgA Nephropathy (IgAN) companies collaborations, Licensing, Acquisition -Deal Value Trends

4.1.1.1. Assessment Summary

4.1.2. IgA Nephropathy (IgAN) Collaboration Deals

4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis

4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis

4.1.2.3. IgA Nephropathy (IgAN) Acquisition Analysis

5. Therapeutic Assessment

5.1. Clinical Assessment of Pipeline Drugs 

5.1.1. Assessment by Phase of Development

5.1.2. Assessment by Product Type (Mono / Combination)

5.1.2.1. Assessment by Stage and Product Type

5.1.3. Assessment by Route of Administration

5.1.3.1. Assessment by Stage and Route of Administration

5.1.4. Assessment by Molecule Type

5.1.4.1. Assessment by Stage and Molecule Type

5.1.5. Assessment by MOA

5.1.5.1. Assessment by Stage and MOA

5.1.6. Assessment by Target

5.1.6.1. Assessment by Stage and Target

6. IgA Nephropathy (IgAN) Late Stage Products (Phase-III)

7. IgA Nephropathy (IgAN) Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. IgA Nephropathy (IgAN) Discontinued Products

13. IgA Nephropathy (IgAN) Product Profiles

13.1. Drug Name: Company 

13.1.1. Product Description

13.1.1.1. Product Overview

13.1.1.2. Mechanism of action

13.1.2. Research and Development

13.1.2.1. Clinical Studies

13.1.3. Product Development Activities

13.1.3.1. Collaboration

13.1.3.2. Agreements

13.1.3.3. Acquisition 

13.1.3.4. Patent Detail

13.1.4. Tabulated Product Summary

13.1.4.1. General Description Table

Detailed information in the report? 

14. IgA Nephropathy (IgAN) Key Companies

15. IgA Nephropathy (IgAN) Key Products

16. Dormant and Discontinued Products

16.1. Dormant Products

16.1.1. Reasons for being dormant

16.2. Discontinued Products 

16.2.1. Reasons for the discontinuation

17. IgA Nephropathy (IgAN) Unmet Needs

18. IgA Nephropathy (IgAN) Future Perspectives

19. IgA Nephropathy (IgAN) Analyst Review  

20. Appendix

21. Report Methodology

21.1. Secondary Research

21.2. Expert Panel Validation 

 

Request for Detailed TOC: https://www.delveinsight.com/sample-request/iga-nephropathy-igan-pipeline-insight

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/iga-nephropathy-igan-pipeline-insight